Serum CEO Adar Poonawalla to get 'Y' category security cover: MHA

Serum Institute is manufacturing the Covishield vaccine in India

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute
Press Trust of India New Delhi
1 min read Last Updated : Apr 28 2021 | 8:12 PM IST

Serum Institute of India's CEO Adar Poonawalla will get 'Y' category security across India by the CRPF, the Union government officials said on Wednesday.

The Union government's decision came after Director, Government and Regulatory Affairs at Pune-based Serum Institute of India (SII), Prakash Kumar Singh hadwritten to Union Home Minister Amit Shah on April 16 requesting security for Poonawalla.

Covishield, one of the two COVID-19 vaccines used in India's COVID-19 vaccination programme, is being manufactured by SII.

In this letter, Singh had stated that Poonawalla has been getting threats from various groups regarding the COVID-19 vaccine supplies.

In this letter, Singh also said, "we are working shoulder to shoulder to fight against COVID-19 pandemic with the Government of India under the dynamic leadership of Prime Minister Narendra Modi Ji.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 28 2021 | 8:10 PM IST

Next Story